PubAg

Main content area

Expression of miRNAs Targeting mTOR and S6K1 Genes of mTOR Signaling Pathway Including miR-96, miR-557, and miR-3182 in Triple-Negative Breast Cancer

Author:
Razaviyan, Javad, Hadavi, Razie, Tavakoli, Rezvan, Kamani, Fereshteh, Paknejad, Maliheh, Mohammadi-Yeganeh, Samira
Source:
Applied biochemistry and biotechnology 2018 v.186 no.4 pp. 1074-1089
ISSN:
0273-2289
Subject:
algorithms, biomarkers, breast neoplasms, cell lines, gene expression, gene expression regulation, genes, messenger RNA, microRNA, neoplasm cells, quantitative polymerase chain reaction, reverse transcriptase polymerase chain reaction, signal transduction, therapeutics
Abstract:
Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer. Aberrant expression of genes in mTOR pathway and their targeting miRNAs plays an important role in TNBC. The aim of this study was to determine the expression of mTOR and S6K1 and their targeting miRNAs in breast cancer cell lines and clinical samples. miRNAs targeting 3′-UTR of mTOR and S6K1 mRNAs were predicted using bioinformatic algorithms. MDA-MB-231, MCF-7, and MCF-10A as well as 20 TNBC samples were analyzed for gene and miRNA expression using quantitative real-time PCR (RT-qPCR). A receiver operating characteristic (ROC) curve analysis was performed for evaluation of candidate miRNAs as diagnostic biomarkers. miR-96 and miR-557 targeting mTOR and S6K1 mRNAs, respectively, were selected, and miR-3182 was selected as the miRNA targeting both genes. The miRNAs were down-regulated in cell lines, while their target mRNAs were up-regulated. Similar findings were observed in clinical samples. The ROC curve analysis revealed decline in expression of these miRNAs. We suggest that miR-96, miR-557, and miR-3182 can be used as inhibitory agents for mTOR and S6K1 in TNBC-targeted therapy.
Agid:
6199625